• 1
    Pedersen NC, Ho E, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790793.
  • 2
    Vahlenkamp TW, Tompkins MB, Tompkins WA. FIV as a model of AIDS pathogenesis studies. In: FriedmanH, SpecterS, BendinelliM, eds. In Vivo Models of HIV Disease and Control. New York: Springer; 2006:239273.
  • 3
    Burkhard M, Obert LA, O'Neil LL, et al. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:347355.
  • 4
    Bendinelli M, Pistello M, Lombardi S, et al. Feline immunodeficiency virus: An interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995;8:87112.
  • 5
    Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 2003;1:1529.
  • 6
    Bucci J, English R, Jordan H, et al. Mucosally transmitted feline immunodeficiency virus induces a CD8+ antiviral response that correlates with reduction of cell-associated virus. J Infect Dis 1998;177:1825.
  • 7
    Willett BJ, Hosie MJ, Callanan JJ, et al. Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. Immunology 1993;78:16.
  • 8
    Lopez M, Soriano V, Lozano S, et al. No major differences in the functional profile of HIV Gag and Nef-specific CD8+ responses between long-term nonprogressors and typical progressors. AIDS Res Hum Retroviruses 2008;24:11851195.
  • 9
    Jagannathan P, Osborne CM, Royce C, et al. Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 2009;83:27282742.
  • 10
    Pedretti E, Passeri B, Amadori M, et al. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet Immunol Immunopathol 2006;109:245254.
  • 11
    Levy J, Crawford C, Hartmann K, et al. American Association of Feline Practitioners' feline retrovirus management guidelines. J Feline Med Surg 2008;10:300316.
  • 12
    Hartmann K, Donath A, Beer B., et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167175.
  • 13
    Hayes KA, Phipps AJ, Francke S, Mathes LE. Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Antimicrob Agents Chemother 2000;44:23992405.
  • 14
    Arai M, Earl DD, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 2002;85:189204.
  • 15
    Hart S, Nolte I. Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT). Zentralbl Veterinarmed A 1995;42:397409.
  • 16
    Hartmann K. Antiviral chemotherapy in veterinary medicine. Proc ACVIM Forum 2008;26:634636.
  • 17
    Haschek WM, Weigel RM, Scherba G, et al. Zidovudine toxicity to cats infected with feline leukemia virus. Fundamental Appl Tox 1990;14:764775.
  • 18
    Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:83338337.
  • 19
    Girard PM, Pegram PS, Diquet B, et al. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: Pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000;23:227235.
  • 20
    Kucera GL, Goff CL, Iyer N, et al. Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity. Antiviral Res 2001;50:129137.
  • 21
    Pharmaceuticals P. Preliminary tolerance of 28-day oral administration of fozivudine to cats. Study Memorandum—Piedmont Pharmaceuticals. 2007–2008.
  • 22
    English RV, Nelson P, Johnson CM, et al. Development of clinical disease in cats experimentally infected with feline immunodeficiency virus. J Infec Dis 1994;170:543552.
  • 23
    Davidson MG, Rottman J, English RV, et al. Feline immunodeficiency virus predisposes cats to acute generalized toxoplasmosis. Am J Pathol 1993;143:14861497.
  • 24
    Tompkins MB, Gebhard DH, Bingham HR., et al. Characterization of monoclonal antibodies to feline T lymphocytes and their use in the analysis of lymphocyte tissue distribution in the cat. Vet Immunol Immunopathol 1990;26:305317.
  • 25
    Mexas AM, Fogle JE, Tompkins WA, Tompkins MB. CD4+CD25+ regulatory T cells are infected and activated during acute FIV infection. Vet Immunol Immunopathol 2008;126:263272.
  • 26
    Fogle JE, Mexas AM, Tompkins WA, Tompkins MB. CD4(+)CD25(+) T regulatory cells inhibit CD8(+) IFN-gamma production during acute and chronic FIV infection utilizing a membrane TGF-beta-dependent mechanism. AIDS Res Hum Retroviruses 2010;26:201216.
  • 27
    Uckun FM, Chen CL, Samuel P, et al. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 2003;47:12331240.
  • 28
    Hayes KA, Lafrado LJ, Erickson JG, et al. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr 1993;6:127134.
  • 29
    Bogner JR, Roecken M, Herrmann DB, et al. Phase I/II trial with fozivudine tidoxil (BM 21.1290): A 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther 1997;2:257264.
  • 30
    Dow SW, Poss ML, Hoover EA. Feline immunodeficiency virus: A neurotropic lentivirus. J Acquir Immune Defic Syndr 1990;3:658668.
  • 31
    English RV, Johnson CM, Gebhard DH, Tompkins MB. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993;67:51755186.
  • 32
    Hartmann K, Ferk G, North TW, Pedersen NC. Toxicity associated with high dosage 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy off attempts to abort early FIV infection. Antiviral Res 1997;36:1125.
  • 33
    Herrmann DBJ, Opitz H-G. BM 21.1290: Pharmacological/toxicological evaluation of a novel candidate anti-AIDS drug. AIDS 1996;1 (Suppl 2):S39.
  • 34
    Bogner JR, Boerner D, Muhlhofer A, et al. Single dose, dose-escalating trial with fozivudine tidoxil (BM 211290). Antivir Ther 1997;2:249256.